ACM
ACRS icon

AlphaCrest Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

AlphaCrest Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-35,000
Closed -$630K – 1355
2021
Q3 		$630K Buy
+35,000
New +$561K 0.03% 818

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AlphaCrest Capital Management's ACRS Position: Q4 2021 in Review

AlphaCrest Capital Management sold out of Aclaris Therapeutics (ACRS) in Q4 2021, closing a stake of 35,000 shares — an estimated $630K sold.

AlphaCrest Capital Management first reported a position in ACRS in Q3 2021 and held it in 1 quarter. The position peaked at $630K in Q3 2021. 133 funds tracked by Wall St. Rank hold ACRS as of Q4 2021.

  • AlphaCrest Capital Management reported no remaining Aclaris Therapeutics position as of Q4 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 35,000 Aclaris Therapeutics shares in Q4 2021, an estimated $630K.
  • AlphaCrest Capital Management first reported a position in Aclaris Therapeutics in Q3 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's Aclaris Therapeutics position peaked at $630K in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2021.

Based on AlphaCrest Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.